HALOZYME THERAPEUTICS ($HALO) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of $2.28 per share, beating estimates of $1.87 by $0.41. The company also reported revenue of $481,000,000, beating estimates of $415,642,860 by $65,357,140.
Stock price change since market close: +3.78%
You can see Quiver Quantitative's $HALO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HALOZYME THERAPEUTICS Insider Trading Activity
HALOZYME THERAPEUTICS insiders have traded $HALO stock on the open market 46 times in the past 6 months. Of those trades, 0 have been purchases and 46 have been sales.
Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:
- HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 38 sales selling 211,923 shares for an estimated $14,447,014.
- CORTNEY CAUDILL (SVP, CHIEF OPERATING OFFICER) has made 0 purchases and 3 sales selling 28,857 shares for an estimated $1,955,159.
- MAHESH KRISHNAN sold 7,304 shares for an estimated $547,800
- BERNADETTE CONNAUGHTON has made 0 purchases and 4 sales selling 4,875 shares for an estimated $335,396.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HALOZYME THERAPEUTICS Hedge Fund Activity
We have seen 335 institutional investors add shares of HALOZYME THERAPEUTICS stock to their portfolio, and 272 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,304,358 shares (-40.5%) from their portfolio in Q1 2026, for an estimated $84,300,657
- MILLENNIUM MANAGEMENT LLC removed 992,664 shares (-67.8%) from their portfolio in Q1 2026, for an estimated $64,155,874
- ASSENAGON ASSET MANAGEMENT S.A. added 976,321 shares (+4578.9%) to their portfolio in Q2 2026, for an estimated $76,416,644
- MIZUHO MARKETS AMERICAS LLC removed 930,463 shares (-70.3%) from their portfolio in Q2 2026, for an estimated $72,827,339
- TWO SIGMA INVESTMENTS, LP added 867,592 shares (+120.9%) to their portfolio in Q1 2026, for an estimated $56,072,470
- MIZUHO MARKETS CAYMAN LP added 834,500 shares (+inf%) to their portfolio in Q2 2026, for an estimated $65,316,315
- JANE STREET GROUP, LLC added 667,363 shares (+406.1%) to their portfolio in Q1 2026, for an estimated $43,131,670
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HALOZYME THERAPEUTICS Congressional Stock Trading
Members of Congress have traded $HALO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HALO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/09.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
HALOZYME THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $HALO recently. We have seen 4 analysts offer price targets for $HALO in the last 6 months, with a median target of $91.5.
Here are some recent targets:
- Vikram Purohit from Morgan Stanley set a target price of $93.0 on 05/12/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 04/29/2026
- Mohit Bansal from Wells Fargo set a target price of $75.0 on 02/19/2026
- Robert Wasserman from Benchmark set a target price of $90.0 on 02/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
